Glibenclamid Genericon en es it fr

Glibenclamid Genericon Brand names, Glibenclamid Genericon Analogs

Glibenclamid Genericon Brand Names Mixture

  • No information avaliable

Glibenclamid Genericon Chemical_Formula


Glibenclamid Genericon RX_link

Glibenclamid Genericon fda sheet

Glibenclamid Genericon msds (material safety sheet)

Glibenclamid_Genericon MSDS

Glibenclamid Genericon Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Glibenclamid Genericon Molecular Weight

494.004 g/mol

Glibenclamid Genericon Melting Point


Glibenclamid Genericon H2O Solubility

4 mg/L

Glibenclamid Genericon State


Glibenclamid Genericon LogP


Glibenclamid Genericon Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Glibenclamid Genericon Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Glibenclamid Genericon Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Glibenclamid Genericon Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Glibenclamid Genericon side effects and Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Glibenclamid Genericon Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Glibenclamid Genericon Organisms Affected

Humans and other mammals